Skip to main content

Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.

Publication ,  Journal Article
Burdmann, EA; Andoh, TF; Nast, CC; Evan, A; Connors, BA; Coffman, TM; Lindsley, J; Bennett, WM
Published in: The American journal of physiology
October 1995

The pathogenesis of renal scarring in chronic cyclosporin nephropathy is unknown. In this study, we evaluated the effects of renin-angiotensin system blockade by enalapril and losartan in a salt-dependent model of cyclosporin-associated chronic tubulointerstitial fibrosis (TIF). Rats kept on normal or low-salt diet were given cyclosporin, cyclosporin+enalapril, cyclosporin+losartan, cyclosporin+enalapril#losartan, or vehicle for 14 and 28 days. Cyclosporin reduced glomerular filtration rate (GFR) in rats fed either diet, but only salt-depleted animals developed significant TIF. Cyclosporin also impaired renal concentrating ability and caused tubular enzymuria. Renin-angiotensin system blockade decreased blood pressure (BP) and promoted afferent arteriolar vasodilatation. Losartan reduced plasma renin activity and prevented cyclosporin-induced increment of cortical alpha 1(I) procollagen mRNA. Renin-angiotensin blockade did not improve GFR and tubular function; however, it strikingly prevented TIF development, even in presence of very low BP. Rats treated with cyclosporin, hydralazine, and furosemide achieved BP values similar to losartan or enalapril groups, but there was no protection against interstitial fibrosis development. These results suggest that cyclosporin-related chronic interstitial injury is mediated by angiotensin II and that the mechanisms promoting the interstitial scarring can be dissociated from glomerular and tubular dysfunction in cyclosporin nephropathy.

Duke Scholars

Published In

The American journal of physiology

ISSN

0002-9513

Publication Date

October 1995

Volume

269

Issue

4 Pt 2

Start / End Page

F491 / F499

Location

united states

Related Subject Headings

  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Burdmann, E. A., Andoh, T. F., Nast, C. C., Evan, A., Connors, B. A., Coffman, T. M., … Bennett, W. M. (1995). Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. The American Journal of Physiology, 269(4 Pt 2), F491–F499.
Burdmann, E. A., T. F. Andoh, C. C. Nast, A. Evan, B. A. Connors, T. M. Coffman, J. Lindsley, and W. M. Bennett. “Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.The American Journal of Physiology 269, no. 4 Pt 2 (October 1995): F491–99.
Burdmann EA, Andoh TF, Nast CC, Evan A, Connors BA, Coffman TM, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. The American journal of physiology. 1995 Oct;269(4 Pt 2):F491–9.
Burdmann, E. A., et al. “Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.The American Journal of Physiology, vol. 269, no. 4 Pt 2, Oct. 1995, pp. F491–99.
Burdmann EA, Andoh TF, Nast CC, Evan A, Connors BA, Coffman TM, Lindsley J, Bennett WM. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. The American journal of physiology. 1995 Oct;269(4 Pt 2):F491–F499.

Published In

The American journal of physiology

ISSN

0002-9513

Publication Date

October 1995

Volume

269

Issue

4 Pt 2

Start / End Page

F491 / F499

Location

united states

Related Subject Headings

  • Cardiovascular System & Hematology